Radius Health (RDUS) Upgraded at BidaskClub

BidaskClub upgraded shares of Radius Health (NASDAQ:RDUS) from a strong sell rating to a sell rating in a research note published on Wednesday morning.

A number of other brokerages have also recently issued reports on RDUS. Zacks Investment Research cut shares of Radius Health from a hold rating to a sell rating in a research note on Wednesday, October 4th. Goldman Sachs Group reissued a neutral rating and issued a $45.00 price objective on shares of Radius Health in a research note on Friday, October 6th. Maxim Group reissued a positive rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Jefferies Group decreased their price objective on shares of Radius Health from $38.00 to $31.00 and set a hold rating on the stock in a research note on Friday, November 3rd. Finally, Cantor Fitzgerald set a $58.00 price objective on shares of Radius Health and gave the company a buy rating in a research note on Thursday, December 7th. Three investment analysts have rated the stock with a sell rating, four have assigned a hold rating and five have issued a buy rating to the company. Radius Health currently has a consensus rating of Hold and a consensus price target of $48.00.

Shares of Radius Health (NASDAQ:RDUS) opened at $31.77 on Wednesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16. The firm has a market cap of $1,405.54, a P/E ratio of -5.85 and a beta of 1.09.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to the consensus estimate of $6.90 million. During the same period last year, the firm posted ($1.07) EPS. analysts predict that Radius Health will post -5.57 EPS for the current year.

In related news, major shareholder Growth N. V. Biotech bought 50,000 shares of the firm’s stock in a transaction on Tuesday, November 14th. The shares were purchased at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the purchase, the insider now owns 5,698,799 shares in the company, valued at approximately $149,593,473.75. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Jesper Hoiland bought 6,800 shares of the firm’s stock in a transaction on Tuesday, November 7th. The shares were bought at an average cost of $29.04 per share, for a total transaction of $197,472.00. Following the purchase, the insider now owns 12,900 shares of the company’s stock, valued at approximately $374,616. The disclosure for this purchase can be found here. Insiders purchased 158,578 shares of company stock worth $4,659,916 over the last three months. 15.00% of the stock is currently owned by insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the business. BB Biotech AG grew its stake in shares of Radius Health by 11.0% during the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock worth $227,905,000 after buying an additional 498,400 shares during the last quarter. Farallon Capital Management LLC grew its stake in shares of Radius Health by 18.3% during the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock worth $166,731,000 after buying an additional 569,300 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Radius Health by 4.5% during the second quarter. Vanguard Group Inc. now owns 3,145,717 shares of the biopharmaceutical company’s stock worth $142,281,000 after buying an additional 135,071 shares during the last quarter. BlackRock Inc. grew its stake in shares of Radius Health by 10.0% during the second quarter. BlackRock Inc. now owns 2,893,641 shares of the biopharmaceutical company’s stock worth $130,881,000 after buying an additional 262,896 shares during the last quarter. Finally, State Street Corp grew its stake in shares of Radius Health by 12.9% during the second quarter. State Street Corp now owns 1,867,531 shares of the biopharmaceutical company’s stock worth $84,473,000 after buying an additional 213,399 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: “Radius Health (RDUS) Upgraded at BidaskClub” was published by Community Financial News and is the property of of Community Financial News. If you are reading this piece on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.com-unik.info/2017/12/30/radius-health-rdus-upgraded-at-bidaskclub.html.

Radius Health Company Profile

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit